ImmuCell Corp. (ICCC)
11.25
-0.08
(-0.71%)
USD |
NASDAQ |
Nov 18, 16:00
11.25
0.00 (0.00%)
After-Hours: 20:00
ImmuCell EPS Diluted (Quarterly) : 0.1024 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.1024 |
| June 30, 2026 | 0.1996 |
| March 31, 2026 | 0.2146 |
| December 31, 2025 | -0.315 |
| September 30, 2025 | -0.0154 |
| June 30, 2025 | 0.0556 |
| March 31, 2025 | 0.1611 |
| December 31, 2024 | 0.0576 |
| September 30, 2024 | -0.0859 |
| June 30, 2024 | -0.1961 |
| March 31, 2024 | -0.0565 |
| December 31, 2023 | -0.1471 |
| September 30, 2023 | -0.1213 |
| June 30, 2023 | -0.1781 |
| March 31, 2023 | -0.2988 |
| December 31, 2022 | -0.2153 |
| September 30, 2022 | -0.0846 |
| June 30, 2022 | -0.0883 |
| March 31, 2022 | 0.0659 |
| December 31, 2021 | 0.0096 |
| September 30, 2021 | 0.0189 |
| June 30, 2021 | 0.0182 |
| March 31, 2021 | -0.0611 |
| December 31, 2020 | 0.0262 |
| September 30, 2020 | -0.0448 |
| Date | Value |
|---|---|
| June 30, 2020 | -0.1062 |
| March 31, 2020 | -0.017 |
| December 31, 2019 | -0.0573 |
| September 30, 2019 | -0.0697 |
| June 30, 2019 | -0.087 |
| March 31, 2019 | 0.0255 |
| December 31, 2018 | -0.1912 |
| September 30, 2018 | -0.0456 |
| June 30, 2018 | -0.1456 |
| March 31, 2018 | -0.0404 |
| December 31, 2017 | -0.04 |
| September 30, 2017 | -0.07 |
| June 30, 2017 | -0.045 |
| March 31, 2017 | 0.12 |
| December 31, 2016 | 0.01 |
| September 30, 2016 | 0.01 |
| June 30, 2016 | -0.0022 |
| March 31, 2016 | 0.11 |
| December 31, 2015 | 0.09 |
| September 30, 2015 | 0.11 |
| June 30, 2015 | 0.03 |
| March 31, 2015 | 0.15 |
| December 31, 2014 | 0.04 |
| September 30, 2014 | 0.0033 |
| June 30, 2014 | -0.10 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | -0.0232 |
| Savara, Inc. | -0.1691 |
| Arrowhead Pharmaceuticals, Inc. | -3.029 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 0.9525M |
| Revenue (Quarterly) | 8.04M |
| Total Expenses (Quarterly) | 7.087M |
| Enterprise Value | 107.09M |
| Gross Profit Margin (Quarterly) | 44.22% |
| Profit Margin (Quarterly) | 11.85% |
| Earnings Yield | 1.79% |
| Operating Earnings Yield | 2.73% |
| Normalized Earnings Yield | 2.274 |